.png)
Investors
>€10B
Total adressable market
China
>€3B
23%
Up affected population
China
16%
Join the forefront of phlebology treatments!
Promising market prospects
-
A huge potential market in Europe : 235m patients
-
Potential for future value creation (~80M€+ projected revenue in 2030)
An exclusive worldwide licence with Inserm
-
Committed founders and a highly qualified and experienced team
-
Six years of research and development in ultrasound technology
An unmet clinical need for a safe, rapid and painless therapy
-
A non-invasive, comfortable approach to meet the needs of patients and doctors
-
A differentiated and validated non-thermal HIFU technology
-
A non-invasive, comfortable approach to meet the needs of patients and doctors
-
A differentiated and validated non-thermal HIFU technology
-
-
Committed founders and a highly qualified and experienced team
-
Six years of research and development in ultrasound technology
-
-
A huge potential market in Europe : 235m patients
-
Potential for future value creation (~80M€+ projected revenue in 2030)
-
Why invest ?
Outstanding Exits
A dynamic and active acquisition market in the last decade
2009
$440m
Covidien acquired VNUS inc.
2014
$220m
Covidien acquired Sapheon
$660
Merz acquired Ulthera inc.
2021
+$500m
BD acquired Venclose
2009
2014
2021
+$500m
BD acquired Venclose
$660m
Merz acquired Ulthera inc.
$220m
Covidien acquired Sapheon
$440m
Covidien acquired VNUS inc.
Outstanding Exits
A dynamic and active acquisition market in the last decade
A breakthrough technology
COMPANIES
NON-INVASIVE
PAINLESS
FAST
OFFICE-BASED
NON-THERMAL
ULTRASOUND
FOAM
GLUE
Concurent
Concurent
THERMAL
THERMAL ABLATION
ULTRASOUND
Concurent
Concurent
July 00th 2024
Lorem ipsum dolor sit amet consectetur. Massa enim viverra viverra sodales lacus.
Lorem ipsum dolor sit amet consectetur. Massa enim viverra viverra sodales lacus. Interdum tristique cursus scelerisque donec mi nunc quis.
July 00th 2024
Lorem ipsum dolor sit amet consectetur. Massa enim viverra viverra sodales lacus.
Lorem ipsum dolor sit amet consectetur. Massa enim viverra viverra sodales lacus. Interdum tristique cursus scelerisque donec mi nunc quis.
July 00th 2024
Lorem ipsum dolor sit amet consectetur massa enim.
June 00th 2024